IntelGenx Technologies Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IGXT research report →
Companywww.intelgenx.com
IntelGenx Technologies Corp. , a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health.
- CEO
- Tommy Kenny
- IPO
- 2007
- Employees
- 48
- HQ
- Montreal, QC, CA
Price Chart
Valuation
- Market Cap
- $29.69M
- P/E
- -2.99
- P/S
- 28.58
- P/B
- -2.42
- EV/EBITDA
- -5.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -66.79%
- Op Margin
- -913.47%
- Net Margin
- -955.44%
- ROE
- 126.70%
- ROIC
- -291.67%
Growth & Income
- Revenue
- $1.04M · 9.37%
- Net Income
- $-9,927,000 · 17.05%
- EPS
- $-0.06 · 21.76%
- Op Income
- $-9,491,000
- FCF YoY
- 31.49%
Performance & Tape
- 52W High
- $0.17
- 52W Low
- $0.16
- 50D MA
- $0.17
- 200D MA
- $0.17
- Beta
- 2.21
- Avg Volume
- 17.56K
Get TickerSpark's AI analysis on IGXT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 19, 24 | ATAI Life Sciences N.V. | other | 0 |
| Nov 28, 23 | ATAI Life Sciences N.V. | buy | 4,053,750 |
| Mar 8, 24 | ATAI Life Sciences N.V. | other | 1,000,000 |
| Oct 6, 23 | ATAI Life Sciences N.V. | other | 8,500,000 |
| Mar 8, 24 | ATAI Life Sciences N.V. | other | 4,000,000 |
| Nov 28, 23 | ATAI Life Sciences N.V. | buy | 750,000 |
| Sep 30, 23 | ATAI Life Sciences N.V. | other | 7,401 |
| Jan 29, 24 | Mayr Clemens | other | 92,510 |
| Jan 29, 24 | Zerbe Horst G | other | 107,435 |
| Jan 29, 24 | Godin Andre | other | 50,000 |
Our IGXT Coverage
We haven't published any research on IGXT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IGXT Report →